Market Access
Week ending August 26, 2026
1. Access and affordability questions this week
- Pharmacy/formulary substitution — 7 questions / 7 responses: Patients asked, “At the pharmacy, they asked if I want Keytruda specifically or can substitute something else—does substitution happen for Keytruda, and why/why not?” Answers consistently referenced prescription wording, country/state rules, insurance/formulary requirements, and pharmacy availability.
- Generic/biosimilar alternatives — 7 questions / 7 responses: Patients asked whether Keytruda is brand-only or has an equivalent generic/biosimilar. Responses generally explained that Keytruda is a biologic and that a conventional generic is not the relevant substitution concept. This is access-relevant because it reflects patients trying to understand why a lower-cost or differently named product may—or may not—be offered.
- Cost, coverage, and compounded alternatives: No direct cost, reimbursement, prior-authorization, copay, patient-assistance, or compounded-product questions were identified this week. Insurance/formulary was mentioned in answers to substitution and treatment-choice questions, but not as the primary patient question.
2. How substitution questions are being handled
The answers are directionally useful but incomplete from an access standpoint. They generally distinguish clinical equivalence from dispensing rules and identify practical drivers. For example, responses say substitution depends on “your country/state, the specific insurance/pharmacy rules, and what the prescriber writes” and whether the pharmacy has the product available.
However, most stop short of a clear patient next step. They do not consistently tell patients to ask:
- whether the offered product is an approved and, where applicable, interchangeable biosimilar;
- whether the change is required by the plan formulary or reflects pharmacy stock;
- what their expected out-of-pocket cost will be; and
- whether the prescriber must approve or rewrite the order.
The responses also discuss Opdivo and Tecentriq mainly as clinically distinct products, not as potential formulary alternatives with different coverage and cost-sharing rules. No compounded alternatives were identified.
3. Off-label coverage risk visibility
No off-label-use questions or off_label tags were present. Consequently, there is no evidence this week that AI responses are explaining—or omitting—coverage implications for off-label treatment. This should be treated as no observed volume, not evidence that the risk is absent.
4. Trend across weeks
- Total responses increased from 60 to 70, while distinct questions remained 10.
- Biosimilar/generic tagging rose slightly from 13 to 14, suggesting steady, modest substitution-related interest.
- Hedging/disclaimer tagging increased from 50 to 58. On access-related questions, this raises concern that patients may receive caveats such as “it depends” without actionable coverage or affordability guidance.
- Inconsistency flags fell from 3 to 2, but neither identified inconsistency is access-relevant.
5. Recommended actions
- Develop a patient-facing formulary-substitution FAQ covering pharmacy stock versus plan-mandated substitution, prescriber authorization, interchangeability, and questions to ask before accepting a change.
- Add cost/coverage prompts: “Is this covered under my plan, what will I owe, and is prior authorization required?”
- Coordinate with the hub/patient-support team to ensure AI-facing materials direct patients to benefits investigation and affordability support when relevant.
- Monitor biosimilar/generic and direct cost questions next week; no off-label-coverage action is indicated until such questions appear.